New malaria vaccine trial results offer a rare piece of good news in the fight against one of the world’s deadliest diseases. A genetically engineered vaccine protected 13 of 15 volunteers from malaria infection in a small first trial, an efficacy of 87%, researchers reported on 19 November 2026.

The results were presented by Dr Sean C. Murphy of the University of Washington School of Medicine and Seattle Children’s Hospital at the annual meeting of the American Society of Tropical Medicine and Hygiene in National Harbor, Maryland.

The trial was small, and the findings have not yet been peer-reviewed. But the design was demanding: volunteers were deliberately exposed to a malaria strain from a different continent than the one used to make the vaccine, three to four months after their last dose.

New Malaria Vaccine Trial: How the Study Worked

Twenty-two healthy adults aged 18 to 45 who had never had malaria took part. They were randomly assigned to receive either the vaccine, Sanaria’s PfSPZ-LARC2, or a saltwater placebo, and neither the volunteers nor the study team knew who had received which.

Twelve to sixteen weeks after the final dose, all 22 were exposed to malaria parasites under controlled conditions in a clinic. All seven placebo recipients became infected. Only two of the 15 vaccinated volunteers did, giving an efficacy of 87%, with a 95% confidence interval of 60 to 99%.

Everyone who became infected was treated promptly and safely, the researchers said. The vaccine was safe and well tolerated in the vaccinated group.

The trial began enrolling volunteers in the summer of 2025. It was run by UW Medicine and partners in the Infectious Diseases Clinical Research Consortium, with support from the US National Institute of Allergy and Infectious Diseases.

How PfSPZ-LARC2 Is Different

Most malaria vaccines in use today, including RTS,S and R21, use a single protein from the parasite to train the immune system. PfSPZ-LARC2 takes a different approach: it uses the whole, live parasite, genetically disabled so it cannot cause disease.

Scientists removed two genes, PfMei2 and PfLINUP, from Plasmodium falciparum, the deadliest human malaria parasite. Without those genes, the parasite stalls and dies in the liver, before it can reach the blood and cause illness. The weakened strain was created in Dr Stefan Kappe’s laboratory at Seattle Children’s and developed for clinical use by Sanaria Inc., a biotechnology company based in Rockville, Maryland.

The challenge in the trial was deliberately tough. The vaccine is built from a West African parasite strain, but volunteers were exposed to 7G8, a strain from Brazil that is genetically distant from it. Protection held up anyway, which matters because many different strains circulate where malaria is common.

What the Results Mean, and What Comes Next

Malaria still infects hundreds of millions of people each year, mostly in sub-Saharan Africa, and kills more than half a million people annually, most of them children under five. Existing vaccines help, but their protection fades, and a vaccine that gives strong, lasting protection has been a long-standing goal.

The new results arrive alongside other encouraging news: a trial published in The Lancet on 19 November found that vaccinating whole communities with the R21 vaccine before the rainy season cut the odds of infection by up to 70% in The Gambia and 30% in Burkina Faso.

For PfSPZ-LARC2, the next steps are bigger trials in places where malaria is common. Sanaria says the vaccine has completed phase 1 trials in Burkina Faso and the United States, and is in a phase 1 trial in Germany and phase 2 trials in Burkina Faso and Mali. A full clinical study report from the Seattle trial is expected in the first quarter of 2027.

For now, the 87% figure comes from 22 people in a phase 1 trial designed mainly to test safety. It is a promising early signal, not proof that the vaccine will work at scale. Larger trials in Africa will decide that.

Sources: University of Washington: Malaria vaccine shows 87% efficacy in clinical trial and Sanaria: Genetically engineered malaria vaccine stops infection in 87% of volunteers. For related vaccine news, see Newsy’s report on India’s first indigenous H5N1 bird flu vaccine.